PL2297359T4 - Profile ekspresji genów do przewidywania skutków raka piersi - Google Patents

Profile ekspresji genów do przewidywania skutków raka piersi

Info

Publication number
PL2297359T4
PL2297359T4 PL09770678T PL09770678T PL2297359T4 PL 2297359 T4 PL2297359 T4 PL 2297359T4 PL 09770678 T PL09770678 T PL 09770678T PL 09770678 T PL09770678 T PL 09770678T PL 2297359 T4 PL2297359 T4 PL 2297359T4
Authority
PL
Poland
Prior art keywords
gene expression
breast cancer
expression profiles
cancer outcomes
predict breast
Prior art date
Application number
PL09770678T
Other languages
English (en)
Other versions
PL2297359T3 (pl
Inventor
Charles M Perou
Joel S Parker
James Stephen Marron
Andrew Nobel
Philip S Bernard
Matthew Ellis
Elaine Mardis
Torsten O Nielsen
Maggie Cheang
Original Assignee
Univ North Carolina Chapel Hill
Univ Utah Res Found
Univ Washington
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill, Univ Utah Res Found, Univ Washington, British Columbia Cancer Agency Branch filed Critical Univ North Carolina Chapel Hill
Publication of PL2297359T3 publication Critical patent/PL2297359T3/pl
Publication of PL2297359T4 publication Critical patent/PL2297359T4/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
PL09770678T 2008-05-30 2009-06-01 Profile ekspresji genów do przewidywania skutków raka piersi PL2297359T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5750808P 2008-05-30 2008-05-30
PCT/US2009/045820 WO2009158143A1 (en) 2008-05-30 2009-06-01 Gene expression profiles to predict breast cancer outcomes
EP09770678.2A EP2297359B1 (en) 2008-05-30 2009-06-01 Gene expression profiles to predict breast cancer outcomes

Publications (2)

Publication Number Publication Date
PL2297359T3 PL2297359T3 (pl) 2014-07-31
PL2297359T4 true PL2297359T4 (pl) 2014-07-31

Family

ID=41202871

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09770678T PL2297359T4 (pl) 2008-05-30 2009-06-01 Profile ekspresji genów do przewidywania skutków raka piersi

Country Status (13)

Country Link
US (8) US9631239B2 (pl)
EP (2) EP2297359B1 (pl)
JP (3) JP5740302B2 (pl)
AU (1) AU2009262894B2 (pl)
CA (1) CA2725760C (pl)
CY (1) CY1114993T1 (pl)
DK (1) DK2297359T3 (pl)
ES (2) ES2650610T3 (pl)
HR (1) HRP20140140T1 (pl)
PL (1) PL2297359T4 (pl)
PT (1) PT2297359E (pl)
SI (1) SI2297359T1 (pl)
WO (1) WO2009158143A1 (pl)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2580969Y2 (ja) 1993-11-01 1998-09-17 株式会社イナックス 便器自動洗浄装置
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
ES2546089T3 (es) * 2009-01-23 2015-09-18 Bergen Teknologioverforing As Métodos para determinar un pronóstico de supervivencia para una paciente con cáncer de mama
US9771618B2 (en) 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
CA2817220C (en) * 2009-11-22 2015-10-20 Azure Vault Ltd. Automatic chemical assay classification
EP2553118B1 (en) 2010-03-31 2014-10-15 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
AU2012211964A1 (en) * 2011-02-04 2013-08-22 Bioarray Genetics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
JP5971769B2 (ja) * 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
US20140228241A1 (en) 2011-07-28 2014-08-14 Sividon Diagnostics Gmbh Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrentbreast cancer
US9517229B2 (en) 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
EP2786140A4 (en) * 2011-11-28 2015-10-28 Nat Res Council Canada PACLITAXEL REACTION MARKERS FOR CANCER
WO2013082440A2 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CA2874492C (en) * 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
US9002438B2 (en) 2012-05-30 2015-04-07 Lucerno Dynamics System for the detection of gamma radiation from a radioactive analyte
US9939533B2 (en) 2012-05-30 2018-04-10 Lucerno Dynamics, Llc System and method for the detection of gamma radiation from a radioactive analyte
US9890430B2 (en) 2012-06-12 2018-02-13 Washington University Copy number aberration driven endocrine response gene signature
JP2015530072A (ja) * 2012-06-29 2015-10-15 ナノストリング テクノロジーズ，インコーポレイティド ゲムシタビン療法による乳癌の治療方法
CN102719547B (zh) * 2012-07-02 2013-10-09 厦门大学 检测her2基因表达水平的实时荧光定量pcr试剂盒
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
US20150299797A1 (en) * 2012-08-24 2015-10-22 University Of Utah Research Foundation Compositions and methods relating to blood-based biomarkers of breast cancer
WO2014071218A2 (en) * 2012-11-02 2014-05-08 University Of Utah Research Foundation Biomarkers for breast cancer and methods of using same
WO2014075067A1 (en) * 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US20150376714A1 (en) 2013-02-01 2015-12-31 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
JP2016519935A (ja) * 2013-05-13 2016-07-11 ナノストリング テクノロジーズ，インコーポレイティド 結節陽性の初期乳癌における再発リスクを予測する方法
SG11201601060RA (en) 2013-08-19 2016-03-30 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of tumors
EP3415639B8 (en) * 2013-08-19 2023-07-12 Shuwen Biotech Co., Ltd. Methods and kits for the molecular subtyping of tumors
EP3036712A4 (en) * 2013-08-20 2017-04-19 The Ohio State Innovation Foundation Methods for predicting prognosis
AU2014317843A1 (en) * 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
KR101560880B1 (ko) 2013-10-15 2015-10-19 이화여자대학교 산학협력단 유방암의 예후 판단을 위한 정보를 제공하는 방법
WO2015084968A1 (en) 2013-12-03 2015-06-11 University Of Massachusetts System and methods for predicting probable relationships between items
CA2934626C (en) * 2014-02-18 2023-08-01 Dignity Health Lkb1 related diagnostics and treatments of cancer
EP3146078B1 (en) * 2014-05-17 2019-11-27 The Regents of the University of California Centromere/kinetochore protein genes as markers for cancer diagnosis and prognosis and for treatment selection
AU2015349870B2 (en) 2014-11-21 2019-09-26 Bruker Spatial Biology, Inc. Enzyme- and amplification-free sequencing
ES2756399T3 (es) 2014-11-24 2020-04-27 Nanostring Technologies Inc Métodos y aparatos para la purificación y formación de imágenes de genes
EP3230466A1 (en) * 2014-12-09 2017-10-18 King's College London Breast cancer treatment with taxane therapy
BR112017012142A2 (pt) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
WO2016137113A1 (ko) * 2015-02-27 2016-09-01 연세대학교 산학협력단 유방암의 예후 및 항암화학요법 사용 여부 판단 장치 및 방법
CN114350752B (zh) 2015-07-17 2025-02-25 布鲁克空间生物学公司 在横切面组织的用户定义区域中的基因表达的同时定量
CA2996426A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
CN109072481B (zh) 2015-12-07 2022-03-18 安大略省癌症研究所 早期乳腺癌内分泌治疗后剩余风险的基因特征
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
CN116200462B (zh) 2016-05-16 2025-10-03 布鲁克空间生物学公司 用于检测样品中目标核酸的方法
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
AU2017361521B2 (en) 2016-11-21 2020-08-27 Bruker Spatial Biology, Inc. Chemical compositions and methods of using same
ES2674327B2 (es) * 2016-11-28 2018-12-17 Geicam - Grupo Español De Investigacion En Cancer De Mama CES: un índice quimioendocrino basado en PAM50 para el cáncer de mama con receptores hormonales positivos con un riesgo intermedio de recidiva
KR101874716B1 (ko) * 2016-12-14 2018-07-04 연세대학교 산학협력단 유방암 분자아형 분류방법 및 이를 이용한 유방암 분자아형 분류 디바이스
US20200017913A1 (en) * 2017-03-02 2020-01-16 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
AU2018230784A1 (en) * 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
KR20200010576A (ko) * 2017-06-16 2020-01-30 난토믹스, 엘엘씨 Praegnant 전이성 유방암 코호트에서의 불량한 결과의 예후 지표 (prognostic indicators of poor outcomes in praegnant metastatic breast cancer cohort)
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
EP3679160A4 (en) 2017-09-08 2021-05-19 Myriad Genetics, Inc. METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE BENEFIT OF CHEMOTHERAPY.
IT201700109459A1 (it) * 2017-09-29 2019-03-29 Univ Degli Studi Di Perugia Metodo per effettuare prognosi del cancro della mammella, kit ed uso di questi
CN111316366A (zh) * 2017-11-08 2020-06-19 皇家飞利浦有限公司 用于同时多变量特征选择、特征生成和样本聚类的方法
WO2019165366A1 (en) * 2018-02-23 2019-08-29 Beth Israel Deaconess Medical Center Drug efficacy evaluations
KR102893736B1 (ko) 2018-05-14 2025-11-28 브루커 스페이셜 바이올로지, 인크. 화학 조성물 및 이의 사용 방법
KR101966589B1 (ko) * 2018-06-20 2019-04-05 연세대학교 산학협력단 유방암 분자아형 분류방법 및 이를 이용한 유방암 분자아형 분류 디바이스
CN113748215B (zh) * 2018-11-04 2024-07-23 Pfs基因组学公司 用于乳腺癌的预后和预测来自辅助放射疗法的益处的方法和基因组分类器
CN109801680B (zh) * 2018-12-03 2023-02-28 广州中医药大学(广州中医药研究院) 基于tcga数据库的肿瘤转移复发预测方法及系统
WO2020178399A1 (en) 2019-03-05 2020-09-10 Norwegian University Of Science And Technology (Ntnu) Breast cancer signature genes
CN109913551A (zh) * 2019-03-26 2019-06-21 深圳大学 乳腺癌分型的核酸组合物、乳腺癌分型试剂盒及其使用方法
US12357250B2 (en) 2019-04-02 2025-07-15 Lucerno Dynamics, Llc System and method of using temporal measurements of localized radiation to estimate the magnitude, location, and volume of radioactive material in the body
CN111508555A (zh) * 2020-04-15 2020-08-07 淮南师范学院 一组用于度量生物分子集的网络拓扑学特性的方法
KR102507489B1 (ko) * 2020-12-24 2023-03-08 가톨릭대학교 산학협력단 진단 분류 장치 및 방법
CN112626218A (zh) * 2021-01-07 2021-04-09 浙江科技学院 一种用于预测胰腺癌转移风险的基因表达分类器、体外诊断试剂盒
CN112735529B (zh) * 2021-01-18 2024-07-30 中国医学科学院肿瘤医院 乳腺癌预后模型的构建方法及应用方法、电子设备
RU2762317C1 (ru) * 2021-02-24 2021-12-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в основном опухолевом узле у больных раком молочной железы
US20240344138A1 (en) * 2021-03-25 2024-10-17 Feng Biosciences, Inc Targeted therapies in cancer
CN114300139A (zh) * 2022-01-13 2022-04-08 澳门科技大学 一种乳腺癌预后模型的构建及其应用方法和存储介质
EP4468965A4 (en) * 2022-01-24 2025-10-22 Sunnybrook Res Inst DEEP LEARNING OF PRETREATMENT QUANTITATIVE MULTI-PARAMETRIC ULTRASOUND IMAGES TO PREDICT BREAST CANCER RESPONSE TO CHEMOTHERAPY
US20250340944A1 (en) * 2022-04-11 2025-11-06 Japanese Foundation For Cancer Research Method to assist in screening for late recurrence of er+ breast cancer, and method for screening therapeutic drugs
WO2023250397A1 (en) * 2022-06-21 2023-12-28 Bioventures, Llc Methods for the molecular subtyping of tumors from archival tissue
CN115144599B (zh) * 2022-09-05 2023-01-06 西湖大学 蛋白组合在制备对儿童甲状腺癌进行预后分层的试剂盒中的用途及其试剂盒、系统
US12308126B1 (en) * 2024-02-13 2025-05-20 Institut Curie Device and method for predicting a relapse of a cancer for a patient
EP4621073A1 (en) 2024-03-22 2025-09-24 Istituto Europeo di Oncologia S.r.l. Method for prognosis of breast cancer
EP4737592A1 (en) 2024-10-31 2026-05-06 GBG Forschungs GmbH Method for predicting a response to systemic treatment in a hormone receptor-positive (hr+) and human epidermal growth factor receptor 2-negative (her2-) breast cancer patient

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US20040235039A1 (en) 1990-03-20 2004-11-25 Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US6025126A (en) 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
CA2527285A1 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
AU2004285103A1 (en) 2003-09-29 2005-05-12 Pathwork Diagnostics, Inc. Systems and methods for detecting biological features
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20080032293A1 (en) 2004-07-15 2008-02-07 The University Of North Carolina At Chapel Hill Housekeeping Genes And Methods For Identifying Same
JP2006141210A (ja) 2004-11-16 2006-06-08 Hitachi Ltd キメラ遺伝子の検出方法
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
CA2635215C (en) 2005-12-23 2016-08-30 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
WO2007076129A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2008111990A1 (en) * 2006-06-14 2008-09-18 Cellpoint Diagnostics, Inc. Rare cell analysis using sample splitting and dna tags
US20090239223A1 (en) 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
EP2155899A2 (en) 2007-04-10 2010-02-24 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
JP5836803B2 (ja) 2008-08-14 2015-12-24 ナノストリング テクノロジーズ， インコーポレイテッド 安定したナノレポーター
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010039275A1 (en) 2008-10-03 2010-04-08 Oligonix, Inc. Method, array and system for detecting intergenic fusions
EP2358199A2 (en) 2008-11-02 2011-08-24 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
EP2486149B1 (en) 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
EP2507396A4 (en) 2009-12-01 2013-06-19 Precision Therapeutics Inc MULTI-MEDICATION RESPONSE MARKERS FOR BREAST CANCER CELLS
EP2558599A4 (en) 2010-04-14 2013-11-13 Nuvera Biosciences Inc METHOD FOR EVALUATING RESPONSE TO CANCER THERAPY
JP5971769B2 (ja) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
WO2012135340A2 (en) 2011-03-28 2012-10-04 Nanostring Technologies, Inc. Compositions and methods for diagnosing cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
CA2874492C (en) 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
JP2015530072A (ja) 2012-06-29 2015-10-15 ナノストリング テクノロジーズ，インコーポレイティド ゲムシタビン療法による乳癌の治療方法
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
AU2014317843A1 (en) 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
CA2966201A1 (en) * 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples

Also Published As

Publication number Publication date
JP2015119716A (ja) 2015-07-02
PL2297359T3 (pl) 2014-07-31
US20230250484A1 (en) 2023-08-10
JP5740302B2 (ja) 2015-06-24
EP2664679A1 (en) 2013-11-20
EP2297359B1 (en) 2013-11-13
US20160168645A1 (en) 2016-06-16
CA2725760A1 (en) 2009-12-30
CY1114993T1 (el) 2016-12-14
CA2725760C (en) 2019-07-02
JP2011524162A (ja) 2011-09-01
US20200040407A1 (en) 2020-02-06
ES2650610T3 (es) 2018-01-19
EP2297359A1 (en) 2011-03-23
US20110145176A1 (en) 2011-06-16
US20190264290A1 (en) 2019-08-29
JP2017127330A (ja) 2017-07-27
US20220213563A1 (en) 2022-07-07
PT2297359E (pt) 2014-03-19
US9631239B2 (en) 2017-04-25
HRP20140140T1 (en) 2014-05-23
EP2664679B1 (en) 2017-11-08
US20160153051A1 (en) 2016-06-02
DK2297359T3 (en) 2014-02-24
ES2457534T3 (es) 2014-04-28
AU2009262894A1 (en) 2009-12-30
JP6140202B2 (ja) 2017-05-31
SI2297359T1 (sl) 2014-05-30
AU2009262894B2 (en) 2014-01-30
US20260098304A1 (en) 2026-04-09
US12595518B1 (en) 2026-04-07
WO2009158143A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
SI2297359T1 (sl) Profili genskega izraĹľanja za napovedovanje izida raka dojke
IL276487B (en) Methods for predicting clinical outcome of cancer
IL212905A0 (en) Individualized cancer dignosis
IL217797A0 (en) Cancer metastasis inhibitor
GB201012379D0 (en) Lipid tumour profile
IL216627A0 (en) Methods for breast cancer risk assessment
IL235795B (en) nano46 genes and methods for predicting breast cancer outcome
PL2460403T3 (pl) Mysi model stłuszczeniowego zapalenia wątroby-raka wątroby
AP3679A (en) Continuous mining
GB201117107D0 (en) Methods for predicting cancer response to EGFR inhibitors
GB0904957D0 (en) Tumour gene profile
GB0804496D0 (en) Treating cancer
ZA201201981B (en) Cancer cell apoptosis
ZA201104932B (en) Phenylimidazole compounds
GB0910751D0 (en) Prostate cancer vaccine
GB201112701D0 (en) Keyboard insert
IL213919A0 (en) Methods to treat cancer
IL214476A0 (en) Method for predicting breast and ovarian cancer risk
EP2321641A4 (en) GENE METHYLATION IN THE DIAGNOSIS OF CANCER
GB0809046D0 (en) Cancer treatment
GB0800934D0 (en) Time zone calculator
GB201002366D0 (en) Cancer prognosis
GB0902065D0 (en) Calculator
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy